Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.48 |
| ▸ | AURKA | O14965 | 4/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | FLT3 | P36888 | 4/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342106 | 0.93 | CSF1R (0.51) | CSF1RRPS6KB1AURKAPDPK1AURKB | |
| SCHEMBL14147163 | 0.90 | KDR (0.44) | CSF1RRPS6KB1AURKAPDPK1AURKB | |
| SCHEMBL12342164 | 0.90 | CSF1R (0.52) | CSF1RRPS6KB1AURKAPDPK1AURKB | |
| SCHEMBL1267328 | 0.86 | CSF1R (0.68) | CSF1RRPS6KB1AURKAPDPK1AURKB | |
| SCHEMBL12338611 | 0.83 | CSF1R (0.40) | CSF1RRPS6KB1KITBRD4 | |
| SCHEMBL12342108 | 0.83 | CSF1R (0.54) | CSF1RRPS6KB1AURKAPDPK1AURKB | |
| SCHEMBL12341853 | 0.82 | CSF1R (0.54) | CSF1RRPS6KB1AURKAAURKBKIT | |
| SCHEMBL12341433 | 0.81 | CSF1R (0.53) | CSF1RRPS6KB1AURKAAURKBKIT | |
| SCHEMBL1268055 | 0.81 | RPS6KB1 (0.42) | RPS6KB1AURKAPDPK1AURKBNTRK1 | |
| SCHEMBL1267604 | 0.79 | CSF1R (0.71) | CSF1RRPS6KB1AURKAPDPK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| WO-2008079909-A1 | PYRROLO [2,3-B] PYRIDINES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CSF1R 2023/4885RPS6KB1 111/4885AURKA 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.